

Boston Scientific Announces 30-Day Safety Data from its TAXUS V Drug-Eluting Stent Clinical Trial

and Washington, D.C. (October 1, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced 30-day safety data from its TAXUS V clinical trial. The trial is assessing the slow-release formulation of the TAXUS™ Express²™ paclitaxel-eluting stent system in 1,172 patients at 66 sites in the U.S. TAXUS V expands on the TAXUS IV pivotal trial by studying a higher-risk patient population, including patients with small vessels, large vessels and long lesions requiring multiple overlapping stents. The Company made the announcement at the annual Transcatheter Cardiovascular Therapeutics symposium in Washington, D.C.

The TAXUS V trial - which includes the use of multiple stents as well as single stents - is designed to assess the safety and efficacy of a paclitaxel-eluting coronary stent in reducing restenosis in de novo lesions 10 - 46 mm in length and 2.25 - 4.0 mm in diameter. It has a primary endpoint of nine-month target vessel revascularization (TVR).

The results support early safety, as demonstrated by a low overall MACE (Major Adverse Cardiac Events) rate of 4.4 percent at 30 days, which is consistent with results from previous TAXUS clinical trials. Thirty-day MACE was 3.7 percent in Group X and 5.1 percent in Group Y (the study remains blinded through the primary endpoint at nine months). The TVR rate was 0.7 percent in Group X and 1.2 percent in Group Y. Stent thromboses were also low, with a rate of 0.5 percent in Group X and 0.7 percent in Group Y.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with clinical trials, the regulatory approval process, commercialization of new technologies and other factors described in the Company's filings with the Securities and Exchange Commission.

<https://news.bostonscientific.com/news-releases?item=58675>